VIDEO: More durable treatment options may help address unmet needs in geographic atrophy

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Unfortunately, the truth is that we currently don’t have anything to actually reverse geographic atrophy, only to slow the progression. So, I think a long-term dream would be really reversal, but the ability to reverse vision loss associated with RPE cell and photoreceptor loss is a pretty lofty goal, and that’s essentially what we would need to do in order to reverse that vision loss. I think also, just thinking kind of more short term, that the agents on the market that we have are wonderful and have really given both physicians and our patients some hope in terms of slowing the progression of this often relentless disease. But ultimately, they do require ongoing injections, which we know from other diseases, such as diabetic retinopathy and neovascular age-related macular degeneration, that these injections on an ongoing basis can be hard for patients. So, finding more durable treatment options or potentially sustained-release drug delivery options of our currently available treatments could really help with this and hopefully is an attainable goal in the intermediate term.